title: A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
abstract: Nasal-type, extranodal NK/T cell lymphoma (ENKTCL) is a special type of lymphomas with geographic and racial specificity. Up to now, the standard first-line treatment is still not unified. In our previous report, the "sandwich" protocol produced good results. Continuing to use the "sandwich" mode, a new chemotherapy composed of L-asparaginase, cisplatin, etoposide and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT) was conducted in more patients with newly diagnosed, I/II stage ENKTCL. The results showed that 66 patients were enrolled. Overall response rate was 86.4% including 83.3% complete response and 3.0% partial remission. With the median follow-up of 23.5 months, 3-year overall survival and 3-year progression-free survival were 70.1% and 67.4%, respectively. The survival rate in stage II and extra-cavity stage I was significantly less than that in limited stage I (p < 0.05). Therefore, we thought that the "sandwich" mode was worthy of being generalized and LVDP combined with CCRT was an effective protocol for I/II stage ENKTCL. But this regimen was not suitable for all stage I/II patients and warrants larger sample and layering investigation. This study was a registered clinical trial with number ChiCTR-TNC-12002353.
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Jiang
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.|Department of Oncology, Dujiangyan Medical Center, Dujiangyan, Sichuan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.affiliation: Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Liu
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Wen-Yan
authors.initials: WY
authors.lastname: Zhang
authors.affiliation: Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Tian
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Yao-Tiao
authors.initials: YT
authors.lastname: Deng
authors.affiliation: Pathology Department, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Sha
authors.initials: S
authors.lastname: Zhao
authors.affiliation: Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
authors.forename: Li-Qun
authors.initials: LQ
authors.lastname: Zou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001215:Asparaginase / Q000494:pharmacology / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use*; D005047:Etoposide / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005047:Etoposide; D003907:Dexamethasone; D001215:Asparaginase; D002945:Cisplatin
keywords: L-asparaginase; cisplatin; etoposide and dexamethasone (LVDP); extranodal NK/T cell lymphoma; nasal-type